NCT00137124View on ClinicalTrials.gov

L-Arginine Metabolism in Essential Hypertension

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Essential Hypertension
Interventions
DRUG

L-Arginine

oral administration of L-arginine for 4 weeks

Trial Locations (1)

91054

CRC, Medizinische Klinik 4 - Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT00137124 - L-Arginine Metabolism in Essential Hypertension | Biotech Hunter | Biotech Hunter